background image
Commercializing
Protons
P.11
A PARTNER FOR LIFE
LETTER CONTINUED FROm P.08
PROTON THERaPY IS ON ITS WaY TO bECOmINg aN ImPORTaNT TOOL FOR TREaTINg CaNCER. WHILE maRKET
development was slow in fiscal 2013, we passed a major clinical milestone and saw several new
business opportunities arise as new groups pressed forward with establishing clinical capability
around the world.
We initiated our investment in this exciting technology in 2007 in response to demand from
clinicians who saw potential in protons to improve treatment precision and outcomes, particularly
in pediatric cases. During 2013 we installed our first commercial ProBeamTM system at Scripps
Proton Therapy Center in San Diego and filed an application for 510(k) clearance with the U.S. Food
and Drug Administration. We hope to see patient treatments begin at Scripps early in 2014. We
are working towards installing systems in St. Petersburg, Russia and Riyadh, Saudi Arabia, and we
are under contract to supply systems for centers planned in the United States in Baltimore, Atlanta
and Dallas.
Varian is uniquely able to capitalize on decades of technological development and clinical expertise
in radiation oncology to offer intensity modulated proton therapy and proton treatment planning
as well as image-guidance and motion management technology. In this way, we offer an advanced
and cost-effective proton treatment capability. We are also focused on driving down the cost of this
technology with more compact designs for two- and one-room systems.
6
$
300m
1
st
VaRIaN-EQUIPPED CENTER TO OPEN IN 2014
PROJECTS UNDER CONTRaCT
aNNUaL maRKET OPPORTUNITY
The promise of proton therapy has captivated clinicians
since Robert R. Wilson wrote about it in 1946. The first
treatment took place at berkeley Radiation Laboratory in
1954. Since then, more than 40 centers have opened to
treat many types of tumors with great precision. Proton
therapy, which minimizes dose to healthy tissue, is seen
as particularly promising for treating delicate tissues in
children whose bodies are still developing.
LETTER CONTINUES ON P.12